

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A peptide selected from the group consisting of An
~~epidermal growth factor receptor (EGFR) derived peptide which is capable of inducing a~~
~~cytotoxic T lymphocyte and an antibody specific for said peptide, wherein the EGFR derived~~
~~peptide consists of at least 8 consecutive amino acid residues derived from the amino acid~~
~~sequence of~~ EGFR₈₀₀₋₈₀₉ (SEQ ID NO: 1), EGFR₁₂₄₋₁₃₂ (SEQ ID NO: 2), EGFR₅₄₋₆₂ (SEQ ID NO:
3), EGFR₄₇₉₋₄₈₈ (SEQ ID NO: 4) or EGFR₁₁₃₈₋₁₁₄₇ (SEQ ID NO: 5).

2-5. (Cancelled)

6. (Currently Amended) A pharmaceutical composition comprising the peptide of
Claim 1, for inducing a cytotoxic T lymphocyte₂ and an antibody specific for said peptide.

7-19. (Cancelled)